Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Quinazolinone-Based Anticancer Agents: Synthesis, Antiproliferative SAR, Antitubulin Activity, and Tubulin Co-crystal Structure.

Dohle W, Jourdan FL, Menchon G, Prota AE, Foster PA, Mannion P, Hamel E, Thomas MP, Kasprzyk PG, Ferrandis E, Steinmetz MO, Leese MP, Potter BVL.

J Med Chem. 2018 Feb 8;61(3):1031-1044. doi: 10.1021/acs.jmedchem.7b01474. Epub 2018 Jan 8.

PMID:
29227648
2.

Synthesis, antitubulin, and antiproliferative SAR of C3/C1-substituted tetrahydroisoquinolines.

Dohle W, Leese MP, Jourdan FL, Major MR, Bai R, Hamel E, Ferrandis E, Kasprzyk PG, Fiore A, Newman SP, Purohit A, Potter BV.

ChemMedChem. 2014 Feb;9(2):350-70. doi: 10.1002/cmdc.201300412. Epub 2014 Jan 16.

PMID:
24436228
3.

STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.

Meyer-Losic F, Newman SP, Day JM, Reed MJ, Kasprzyk PG, Purohit A, Foster PA.

PLoS One. 2013 Dec 6;8(12):e80305. doi: 10.1371/journal.pone.0080305. eCollection 2013.

4.

Tetrahydroisoquinolinone-based steroidomimetic and chimeric microtubule disruptors.

Leese MP, Jourdan FL, Major MR, Dohle W, Hamel E, Ferrandis E, Fiore A, Kasprzyk PG, Potter BV.

ChemMedChem. 2014 Jan;9(1):85-108, 1. doi: 10.1002/cmdc.201300261. Epub 2013 Oct 9.

5.

CDC25 inhibitors as anticancer agents are moving forward.

Brezak MC, Kasprzyk PG, Galcera MO, Lavergne O, Prévost GP.

Anticancer Agents Med Chem. 2008 Dec;8(8):857-62. Review.

PMID:
19075568
6.

IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells.

Brezak MC, Valette A, Quaranta M, Contour-Galcera MO, Jullien D, Lavergne O, Frongia C, Bigg D, Kasprzyk PG, Prevost GP, Ducommun B.

Int J Cancer. 2009 Mar 15;124(6):1449-56. doi: 10.1002/ijc.24080.

7.

IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents.

Liberatore AM, Coulomb H, Pons D, Dutruel O, Kasprzyk PG, Carlson M, Nelson AS, Newman SP, Stengel C, Auvray P, Hesry V, Foll B, Narboux N, Morlais D, Le Moing M, Bernetiere S, Dellile R, Camara J, Ferrandis E, Bigg DC, Prévost GP.

Mol Cancer Ther. 2008 Aug;7(8):2426-34. doi: 10.1158/1535-7163.MCT-08-0208. Erratum in: Mol Cancer Ther. 2009 Jan;8(1):274.

8.

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers.

Newman SP, Foster PA, Ho YT, Day JM, Raobaikady B, Kasprzyk PG, Leese MP, Potter BV, Reed MJ, Purohit A.

Br J Cancer. 2007 Dec 17;97(12):1673-82. Epub 2007 Nov 20.

9.

2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique.

Foster PA, Ho YT, Newman SP, Kasprzyk PG, Leese MP, Potter BV, Reed MJ, Purohit A.

Breast Cancer Res Treat. 2008 Sep;111(2):251-60. Epub 2007 Oct 24.

PMID:
17957467
10.

3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity.

Bubert C, Leese MP, Mahon MF, Ferrandis E, Regis-Lydi S, Kasprzyk PG, Newman SP, Ho YT, Purohit A, Reed MJ, Potter BV.

J Med Chem. 2007 Sep 6;50(18):4431-43. Epub 2007 Aug 15.

PMID:
17696419
11.

Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex.

Prévost GP, Lonchampt MO, Holbeck S, Attoub S, Zaharevitz D, Alley M, Wright J, Brezak MC, Coulomb H, Savola A, Huchet M, Chaumeron S, Nguyen QD, Forgez P, Bruyneel E, Bracke M, Ferrandis E, Roubert P, Demarquay D, Gespach C, Kasprzyk PG.

Cancer Res. 2006 Sep 15;66(18):9227-34.

12.

Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases.

Brezak MC, Quaranta M, Contour-Galcera MO, Lavergne O, Mondesert O, Auvray P, Kasprzyk PG, Prevost GP, Ducommun B.

Mol Cancer Ther. 2005 Sep;4(9):1378-87.

13.

Membrane structure modulation, protein kinase C alpha activation, and anticancer activity of minerval.

Martínez J, Vögler O, Casas J, Barceló F, Alemany R, Prades J, Nagy T, Baamonde C, Kasprzyk PG, Terés S, Saus C, Escribá PV.

Mol Pharmacol. 2005 Feb;67(2):531-40. Epub 2004 Nov 5.

14.

BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.

Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Camara J, Kasprzyk PG, Prévost G, Bigg DC.

Cancer Res. 2004 Jul 15;64(14):4942-9.

15.

A novel synthetic inhibitor of CDC25 phosphatases: BN82002.

Brezak MC, Quaranta M, Mondésert O, Galcera MO, Lavergne O, Alby F, Cazales M, Baldin V, Thurieau C, Harnett J, Lanco C, Kasprzyk PG, Prevost GP, Ducommun B.

Cancer Res. 2004 May 1;64(9):3320-5.

16.

The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.

Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Kasprzyk PG, Bailly C, Camara J, Bigg DC.

Anticancer Drugs. 2001 Jan;12(1):9-19.

PMID:
11272292
17.

Homocamptothecins: E-ring modified CPT analogues.

Lavergne O, Demarquay D, Kasprzyk PG, Bigg DC.

Ann N Y Acad Sci. 2000;922:100-11. Review.

PMID:
11193885
18.

Drug-induced inhibition of the peripheral-type benzodiazepine receptor expression and cell proliferation in human breast cancer cells.

Papadopoulos V, Kapsis A, Li H, Amri H, Hardwick M, Culty M, Kasprzyk PG, Carlson M, Moreau JP, Drieu K.

Anticancer Res. 2000 Sep-Oct;20(5A):2835-47.

PMID:
11062691
19.

Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.

Lesueur-Ginot L, Demarquay D, Kiss R, Kasprzyk PG, Dassonneville L, Bailly C, Camara J, Lavergne O, Bigg DC.

Cancer Res. 1999 Jun 15;59(12):2939-43.

20.

Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.

Lavergne O, Lesueur-Ginot L, Pla Rodas F, Kasprzyk PG, Pommier J, Demarquay D, Prévost G, Ulibarri G, Rolland A, Schiano-Liberatore AM, Harnett J, Pons D, Camara J, Bigg DC.

J Med Chem. 1998 Dec 31;41(27):5410-9.

PMID:
9876111
21.

Activity of anti-erbB-2 recombinant toxin OLX-209 on lung cancer cell lines in the absence of erbB-2 gene amplification.

Kasprzyk PG, Sullivan TL, Hunt JD, Gubish CT, Scoppa CA, Oelkuct M, Bird R, Fischer PH, Siegfried JM, King CR.

Clin Cancer Res. 1996 Jan;2(1):75-80.

22.

Preclinical testing of an anti-erbB-2 recombinant toxin.

King CR, Kasprzyk PG, Fischer PH, Bird RE, Turner NA.

Breast Cancer Res Treat. 1996;38(1):19-25. Review.

PMID:
8825119
23.

Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.

Reiter Y, Brinkmann U, Jung SH, Lee B, Kasprzyk PG, King CR, Pastan I.

J Biol Chem. 1994 Jul 15;269(28):18327-31.

24.

In vitro and in vivo activity of a recombinant toxin, OLX-209, which targets the erbB-2 oncoprotein.

Fischer PH, Bird RE, Kasprzyk PG, King CR, Turner NA, Pastan I, Kihara A, Batra J.

Adv Enzyme Regul. 1994;34:119-28.

PMID:
7942269
25.

Effect of gastrin-releasing peptide on the pancreatic tumor cell line (Capan).

Avis I, Jett M, Kasprzyk PG, Cuttitta F, Treston AM, Maneckjee R, Mulshine JL.

Mol Carcinog. 1993;8(4):214-20.

PMID:
8280369
26.

A mitogenic peptide amide encoded within the E peptide domain of the insulin-like growth factor IB prohormone.

Siegfried JM, Kasprzyk PG, Treston AM, Mulshine JL, Quinn KA, Cuttitta F.

Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8107-11.

27.

Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.

Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR.

Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5867-71.

28.

Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies.

Kasprzyk PG, Song SU, Di Fiore PP, King CR.

Cancer Res. 1992 May 15;52(10):2771-6.

29.

Alpha-amidation of peptide hormones in lung cancer.

Quinn KA, Treston AM, Scott FM, Kasprzyk PG, Avis I, Siegfried JM, Mulshine JL, Cuttitta F.

Cancer Cells. 1991 Dec;3(12):504-10. Review.

PMID:
1668141
30.

Preclinical evaluation of an anti-autocrine growth factor monoclonal antibody for treatment of patients with small-cell lung cancer.

Avis IL, Kovacs TO, Kasprzyk PG, Treston AM, Bartholomew R, Walsh JH, Cuttitta F, Mulshine JL.

J Natl Cancer Inst. 1991 Oct 16;83(20):1470-6.

PMID:
1656058
31.

Lung cancer: rational strategies for early detection and intervention.

Mulshine JL, Treston AM, Scott FM, Avis I, Boland C, Phelps R, Kasprzyk PG, Nakanishi Y, Cuttitta F.

Oncology (Williston Park). 1991 May;5(5):25-32; discussion 32-3, 37.

PMID:
1832003
32.

Implications of erbB-2 overexpression for basic science and clinical medicine.

King CR, Kraus MH, DiFiore PP, Paik S, Kasprzyk PG.

Semin Cancer Biol. 1990 Oct;1(5):329-37. Review.

PMID:
2103506
33.

Autocrine growth factors as therapeutic targets in lung cancer.

Mulshine JL, Treston AM, Natale RB, Kasprzyk PG, Avis I, Nakanishi Y, Cuttitta F.

Chest. 1989 Jul;96(1 Suppl):31S-34S. Review. No abstract available.

PMID:
2661168
34.

Autocrine growth factors and lung cancer.

Mulshine JL, Natale RB, Avis I, Treston AM, Kasprzyk PG, Nakanishi Y, Sausville EA, Trepel JB, Cuttitta F.

Cancer Treat Res. 1989;45:107-22. Review. No abstract available.

PMID:
2577167
35.

Solid-phase peptide quantitation assay using labeled monoclonal antibody and glutaraldehyde fixation.

Kasprzyk PG, Cuttitta F, Avis I, Nakanishi Y, Treston A, Wong H, Walsh JH, Mulshine JL.

Anal Biochem. 1988 Oct;174(1):224-34.

PMID:
3146232
36.

Posttranslational processing of endogenous and of baculovirus-expressed human gastrin-releasing peptide precursor.

Lebacq-Verheyden AM, Kasprzyk PG, Raum MG, Van Wyke Coelingh K, Lebacq JA, Battey JF.

Mol Cell Biol. 1988 Aug;8(8):3129-35.

37.

Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.

Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale RB, Maneckjee R, Avis I, Treston AM, Gazdar AF, Minna JD, Cuttitta F.

J Clin Invest. 1988 Jul;82(1):354-9.

38.

Consideration of the chemistry of solid-phase matrix interaction leads to improved quantitation of neuropeptides.

Kasprzyk PG, Cuttitta F, Treston AM, Avis I, Nakanishi Y, Wong H, Walsh JH, Mulshine JL.

Ann N Y Acad Sci. 1988;547:41-53. No abstract available.

PMID:
3239893
39.

Growth factor effects on small cell lung cancer cells using a colorimetric assay: can a transferrin-like factor mediate autocrine growth?

Nakanishi Y, Cuttitta F, Kasprzyk PG, Avis I, Steinberg SM, Gazdar AF, Mulshine JL.

Exp Cell Biol. 1988;56(1-2):74-85.

PMID:
2846378
40.
41.

Fluorescence energy transfer experiments with Escherichia coli carbamoyl-phosphate synthetase.

Kasprzyk PG, Anderson PM, Villafranca JJ.

Biochemistry. 1983 Apr 12;22(8):1877-82.

PMID:
6342671

Supplemental Content

Loading ...
Support Center